#4-76E. Breaking the Glucocorticoid Trap: Secukinumab for Relapsed Polymyalgia Rheumatica (NEJM, 2026)

Are we finally breaking the cycle of glucocorticoid dependence in managing polymyalgia rheumatica (PMR)? In this episode, we explore a phase 3 randomized controlled trial investigating the efficacy of secukinumab, an IL-17A inhibitor, for patients with recently relapsed PMR. The study randomized 381 patients to receive either secukinumab or a placebo, alongside a 24-week glucocorticoid taper. The findings revealed that secukinumab significantly improved sustained remission rates at week 52 and reduced the annual cumulative glucocorticoid dose1more_horiz. The most critical clinical takeaway is that secukinumab effectively doubled the sustained remission rate to approximately 41% compared to 20% in the placebo group, strongly supporting its potential as a novel glucocorticoid-sparing agent. However, when critically appraising this study, clinicians should note the higher dropout rate in the placebo arm and the lack of efficacy data beyond one year, which might limit our understanding of long-term outcomes. For practicing physicians, this paper is highly significant because it introduces a powerful new targeted therapy to overcome the challenges of steroid toxicity and tapering, potentially changing the standard of care for relapsing PMR.

Citation: Stone, J.H., et al. Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. The New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2602567

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.